Solid Bio’s long, troubled slog through the clinic yields 'encouraging' early data and no new safety concerns. It's not winning over investors yet

Amber Tong

Those who have been following the gene therapy space would be familiar with Solid Bio’s IGNITE-DMD trial. Beset with safety issues, the Phase I/II study …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Solid Bio’s long, troubled slog through the clinic yields 'encouraging' early data and no new safety concerns. It's not winning over investors yet

Amber Tong

Sign up to read this article for free.

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Acadia snaps up an essential tremor drug after field's summer setbacks

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank

Sol­id Bio’s long, trou­bled slog through the clin­ic yields 'en­cour­ag­ing' ear­ly da­ta and no new safe­ty con­cerns. It's not win­ning over in­vestors yet

Amber Tong

Sign up to read this article for free.

more like this

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

Solid Bio’s long, troubled slog through the clinic yields 'encouraging' early data and no new safety concerns. It's not winning over investors yet

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Acadia snaps up an essential tremor drug after field's summer setbacks

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank